In an orthotopic and more aggressive model of retinoblastoma, subconjunctival nutlin-3aoc administration combined with systemic topotecan, showed significant improvement in survival due to tumor necrosis and activation of the p53 pathway compared to that observed using multimodal chemotherapeutic regimens (VCE or carboplatin/topotecan) (45). This evidence concerns the gene TP53 and retinoblastoma.